Pure Global
NCT06422208

Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease

A Phase 1 Clinical Trial of Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease
Penelope J. Hallett, Ph.D.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Autologous midbrain dopamine neurons
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Penelope J. Hallett, Ph.D.
Funder
Mclean Hospital
Location
Boston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
Aug 01, 2027
Enrollment
6 participants
Primary outcome

Safety: number and severity of adverse events and serious adverse events

Summary

This research study is evaluating an investigational cell product called autologous induced
 pluripotent stem cell-derived dopamine neurons. This research study is a single-center Phase
 1 clinical trial, which will test the safety of injecting the investigational cell product
 into the brain of subjects with Parkinson's disease.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06422208
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06422208 through Pure Global AI's free database. This Phase 1 trial is sponsored by Penelope J. Hallett, Ph.D. and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 6 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.